BIOG_B Q3 sales up 23% as EBIT margin reaches 33%
BIOG_B reported third-quarter sales growth to SEK 400 million, with double-digit expansion in both segments and every region. Q4 Asia Pacific growth is expected to pick up.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Third-quarter sales climbed 23% to SEK 400 million, and the EBIT margin hit 33%, according to TradingView. Growth reached double digits in both business segments and across every region. Management anticipates faster expansion in Asia Pacific during the fourth quarter. Meanwhile, sizable EMEA pediatric orders moved from the fourth quarter into the third. The shift pulled some revenue forward into the current period.
why it matters
A strong quarter with a high margin points to solid underlying demand. Moving orders from the fourth quarter into the third means part of the revenue was booked earlier, which could affect comparisons with the next period. The news matters mainly for the company's shareholders and a narrow market segment.
market impact
BIOG B shares: strong results and high margin support investor interest in the stock
tags
instruments
sources
- BIOG_B: Q3 sales grew 23%, EBIT margin reached 33%, and Q4 Asia Pacific growth is expected to accelerate — TradingView, 22 October 2026 at 08:59 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗